Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease

Journal of Inherited Metabolic Disease

Volumn 27, Issue 6, 2004, Pages 757-766

  Elstein, D ^a   Hollak, C ^b   Aerts, J M F G ^b   van Weely, S ^b   Maas, M ^b   Cox, T M ^c   Lachmann, R H ^c   Hrebicek, M ^d   Platt, F M ^e   Butters, T D ^e   Dwek, R A ^e   Zimran, A ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d Charles University in Prague and General University Hospital in Prague   (Czech Republic)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CHITOTRIOSIDASE; CODEINE PHOSPHATE; HEMOGLOBIN; LOPERAMIDE; MIGLUSTAT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; BODY WEIGHT DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; FREQUENCY ANALYSIS; GAUCHER DISEASE; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN DETERMINATION; HUMAN; LIVER WEIGHT; LONG TERM CARE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; ORGAN SIZE; PATIENT MONITORING; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PREVALENCE; SPLEEN WEIGHT; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; TREMOR; WEIGHT REDUCTION;

1-DEOXYNOJIRIMYCIN; ADMINISTRATION, ORAL; ELECTROMYOGRAPHY; ENZYME INHIBITORS; GAUCHER DISEASE; HEMOGLOBINS; HEXOSAMINIDASES; HUMANS; LIVER; MAGNETIC RESONANCE IMAGING; NEURAL CONDUCTION; PLATELET COUNT; SPLEEN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 7244254360     PISSN: 01418955     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BOLI.0000045756.54006.17     Document Type: Article

References (14)

1. Cox TM, Schofield JP (1997) Gaucher's disease: Clinical features and natural history. In: Zimran A, ed. Baillière's Clinical Haematology: Gaucher's Disease. London: Baillère-Tindall, 657-689.
2. Cox TM, Lachmann R, Hollak C, et al (2000) Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355(9214): 1481-1485.
3. Cox TM, Aerts JMFG, Andria G, et al (2003) The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type 1 (non-neuronopathic) Gaucher disease: A position statement. J Inherit Metab Dis 26: 513-526.
4. Elstein D, Hadas-Halpern I, Itzchaki M, et al (1996) Effect of low-dose ERT on bones in Gaucher disease patients with severe skeletal involvement. Blood Cells Mol Dis 22:104-111.
5. Hollak C, van Weely S, van Oers MH, Aerts J (1994) Marked elevation of plasma chitotriosidase activity: A novel hallmark of Gaucher disease. J Clin Invest 93: 1288-1292.
6. Hollak CEM, Maas JM, Aerts JM (2001) Clinically relevant therapeutic endpoints in type 1 Gaucher disease. J Inherit Metab Dis 24 (supplement 2): 97-105.
7. Johnson LA, Hoppel BE, Gerard EL, et al (1992) Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease. Radiology 182(2): 451-455.
8. Maas M, Akkerman EM, Venema HW, Stoker J, Den Heeten GJ (2001) Dixon quantitative chemical shift MRI for bone marrow evaluation in the lumbar spine: A reproducibility study in healthy volunteers. J Comput Assist Tomogr 25: 691-697.
9. Maas M, Hollak CE, Akkerman EM, Aerts JM, Stoker J, Den Heeten GJ (2002) Quantification of skeletal involvement in adults with type I Gaucher's disease: Fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. Am J Roentgenol 179(4): 961-965.
10. Miller SP, Zirzow GC, Doppelt SH, Brady RO, Barton NW (1996) Analysis of the lipids of normal and Gaucher bone marrow. J Lab Clin Med 127(4): 353-358.
11. Platt F, Neises GR, Dwek R, Butters T (1994) N Butyldeoxynojirimycin is a novel inhibitor of glycolipid synthesis. J Biol Chem 269(11): 8362-8365.
12. Platt F, Neises GR, Reinkensmeier G, et al (1997) Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science 276: 428-431.
13. Platt F, Jeyakumar M, Andersson U, et al (2003) Substrate reduction therapy in mouse models of the glycosphingolipidoses. Phil Trans R Soc Lond B 358: 947-954.
14. Vellodi A, Bembi B, de Villemeur TB, et al (2001) Management of neuronopathic Gaucher disease: A European consensus. J Inherit Metab Dis 24(3): 319-327.